FDA expedites review of Sanofi-Regeneron colon cancer drug

04/5/2012 | InPharm.com · Reuters

The FDA granted priority-review designation for Sanofi and Regeneron's colorectal cancer drug Zaltrap, or aflibercept. The partners said the drug failed to meet the main endpoint of extending overall survival in patients with metastatic androgen-independent prostate cancer in a late-stage trial.

View Full Article in:

InPharm.com · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA